Evidence map›Paper›PMID 35329160›Full record

ArticleInternational journal of environmental research and public health2022

Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians.

Anju Murayama, Yuki Senoo, Kayo Harada, Yasuhiro Kotera, Hiroaki Saito, Toyoaki Sawano, Yosuke Suzuki, Tetsuya Tanimoto, Akihiko Ozaki

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Anju MurayamaMedical Governance Research Institute, Minato-ku, Tokyo 108-0074, Japan.ORCID 0000-0002-4279-4748
Yuki SenooMedical Governance Research Institute, Minato-ku, Tokyo 108-0074, Japan.ORCID 0000-0001-7289-5016
Kayo HaradaMedical Governance Research Institute, Minato-ku, Tokyo 108-0074, Japan.
Yasuhiro KoteraSchool of Health Sciences, University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-0251-0085
Hiroaki SaitoDepartment of Gastroenterology, Sendai Kousei Hospital, Sendai 980-0873, Japan.ORCID 0000-0002-0824-454X
Toyoaki SawanoDepartment of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki 972-8322, Japan.
Yosuke SuzukiMedical Governance Research Institute, Minato-ku, Tokyo 108-0074, Japan.
Tetsuya TanimotoMedical Governance Research Institute, Minato-ku, Tokyo 108-0074, Japan.
Akihiko OzakiMedical Governance Research Institute, Minato-ku, Tokyo 108-0074, Japan.ORCID 0000-0003-4415-9657
Medical Governance Research Institute · JPJyoban Hospital of Tokiwa Foundation · JPSendai Kousei Hospital · JPTohoku University · JPUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAwareness and perceptions of financial conflicts of interest (FCOI) between pharmaceutical companies (Pharma) and healthcare domains remain unclear in Japanese cancer patient communities. This study aimed to assess awareness (RQ1), the influence of FCOI on physician trustworthiness (RQ2), and their perception (RQ3) among the Japanese cancer patient advocacy group members.

methodsA cross-sectional study using a self-administered survey was conducted with a Japanese cancer patient advocacy group between January and February 2019. The main outcome measures included awareness and perceptions of physician-Pharma interactions, their impact on physician trustworthiness, and attitudes towards FCOI among medical and other professions. Furthermore, we performed thematic analyses on the comments which responders provided in the surveys.

resultsAmong the 524 contacted members, 96 (18.3%) completed the questionnaire, including 69 (77.5%) cancer patients. In RQ1, most of the respondents were aware of physician-Pharma interactions, although the extent differed based on the nature of the interaction. Furthermore, the respondents mainly considered these interactions influential on clinical practice (RQ2) and agreed to the need for further regulation of physician-Pharma interactions (QR3). In qualitative analyses (

conclusionsMost respondents were generally aware of physician-Pharma-associated FCOI and perceived them negatively. Additionally, participants appeared supportive of further FCOI regulation to protect patient-centred care. ABBREVIATIONS: FCOI-financial conflicts of interest; United States-US; Pharma-pharmaceutical companies; RQ-research question.

Indexed as

NeoplasmsPhysiciansCross-Sectional StudiesDrug IndustryHumansJapanPatient AdvocacyPharmaceutical PreparationsPharmaceutical Preparationsconflict of interestethicsfinancial relationshipJapanpatient-centred carepharmaceutical industry

Identifiers

PMID35329160
PMCPMC8952770
OpenAlexW4220871887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.